North America Analysis

Research & Innovation News

Open Access Government has a large variety of Scientific Research and Innovation information that is available in this category.

This section explores the latest breakthroughs in all aspects of science: including Biology, Chemistry, Physics, Psychology and Sociology. There is extensive research on psychological and social patterns that occur in everyday life.

Information is available on scientific policies that the government might adopt. Along with the changes and developments of global space policy. We cover the ongoing rise of anti-microbial resistance (AMR) and cancer research breakthroughs along with countries and their own individual research priorities.

Within this category we explore the massive increase and growth in CBD research and production, there is a lot of interesting information available.

epilepsy research, university of nebraska

Epilepsy research: Improving infrastructure & management

Arun Swaminathan MD, Assistant Professor of Neurology and Epilepsy at the University of Nebraska Medical Center, considers the importance of improving infrastructure and management of epilepsy research.
farmed salmon and trout, delousing

Oceans: Delousing farmed salmon and trout

Here, we find out about delousing farmed salmon and trout, including the importance of fish welfare in this special oceans focus.
Nitric Oxide Formation

Nitric Oxide Formation Research

Dr Alan Schechter of the Molecular Medicine Branch at the National Institutes of Health in Bethesda, Maryland and his colleagues discuss research during the last two decades that has revealed a second major pathway for Nitric Oxide formation in mammals.
reproductive medicine, fertility clinics

How valuable are randomised controlled trials in reproductive medicine?

Professor Darren Griffin reflects on how patients in fertility clinics should interpret the scientific evidence base when even the experts can’t seem to agree.
bharat biotech COVID vaccine, covaxin

Bharat Biotech COVID vaccine shows 81% efficacy at Phase Three

The Bharat Biotech COVID vaccine, COVAXIN, appears to be 81% efficient against the virus in Phase Three of clinical trials.
the astrazeneca vaccine, covid

The AstraZeneca vaccine is atleast 60% effective for people aged 70 and over

A study examining older people in the UK found that only one dose of the AstraZeneca vaccine is atleast 60% effective for people aged 70 and over.
genetics of eating disorders, depression

Researchers investigate the genetics of eating disorders

An international research team have discovered that the genetics of eating disorders and some psychiatric disorders have some similarities, raising new questions about treatment for both.
predict severe covid, blood

Scientists find that elevated neutrophils can predict severe COVID and death

Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.
johnson & johnson vaccine, johnson vaccine

FDA approves the Johnson & Johnson vaccine for use

The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.
convalescent plasma donation, plasma

The window for convalescent plasma donation is just under two months

New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.
doses of the astrazeneca vaccine, germany

1.17 million doses of the AstraZeneca vaccine could expire in Germany

Germans have only taken 270,986 AstraZeneca doses so far, leaving roughly 1.17 million doses in storage across the country - but these shots are due to expire in less than six months.
EU research

Horizon Europe: EU research & innovation

Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth, describes Horizon Europe and scaling up high-impact and breakthrough research & innovation.
UK vaccine hesitancy, REACT study

REACT study: UK vaccine hesitancy is the highest in London

New data from the REACT study finds that 14% of the UK population have antibodies against COVID-19 now, but that vaccine hesitancy is currently highest in London.
starting grants for researchers, horizon europe

Horizon Europe launches €619 million Starting Grants for researchers

The first Horizon Europe grants will be launched today (25 February), with Starting Grants for researchers worth €619 million available.
californian covid mutation, covid

The Californian COVID mutation is more infectious

The Californian COVID mutation appears to be as infectious as the UK or South African mutations - but does it have the potential to be more deadly?
johnson & Johnson, mutation

FDA reveals that Johnson & Johnson vaccine is 86% effective

New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.
biomedical innovations

Targeted policy support for emerging biomedical innovations

Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
biomodifying technologies, gene therapy

The promises and challenges of biomodifying technologies for the UK

Michael Morrison, Senior Researcher in Social Science at the Centre for Health, Law and Emerging Technologies (HeLEX), University of Oxford, sheds light on the promises as well as biomodifying technologies for the UK.
lead batteries

Accelerating innovation: Lead batteries look to the future

Dr Alistair Davidson, Director, Consortium for Battery Innovation, describes accelerating innovation when it comes to the use of lead batteries in the future.
likelihood of severe COVID, genetic research

Scientists use machine learning to identify likelihood of severe COVID

The research team believe that some people have a genetic predisposition that increases likelihood of severe COVID, which may be crucial to understanding how mutations could change outcomes.

Follow Open Access Government